Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. - Test2 - elhamkhani - TriplyDB

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.

http://www.wikidata.org/entity/Q38391922

about

Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment.Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.Nivolumab in renal cell carcinoma: latest evidence and clinical potential.Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.What advances have been made in immune-therapy for renal cell carcinoma?Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?Immune Modulation Therapy and Imaging: Workshop Report.Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy.Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015.Posttraumatic Stress Disorder: An Immunological Disorder?Trial watch: Immune checkpoint blockers for cancer therapy.Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.Pushing the limits of immune-related response: a case of "extreme pseudoprogression".PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy.Role of noninvasive molecular imaging in determining response Immune Checkpoint Inhibition in Head and Neck Cancer

P2860

Q33832752-6221DC09-1C6C-4CE9-91FC-488F87E34B64 Q36413957-C74A15D8-79C3-4CE6-A3E6-4082481C68BB Q37620907-B970F0EC-2C84-4141-B9D7-0B32450A8941 Q37664203-BC0957C7-33AD-447E-8090-A8A096988792 Q37698611-DFB0B140-9BCC-49AD-8B80-439D1F5ADEE4 Q38374778-2701878E-E5B9-4793-A59D-680729F2E795 Q38734141-868191CB-7DD1-4DAD-BFFE-CE86C088F09F Q38759282-E57491E0-8424-4E3E-966F-31FCE95E33B7 Q39120161-0CE59218-EA2C-4C9B-9CA8-433277526095 Q40089191-AC4D0C16-1C2C-4B11-A6D0-25D7D840CF2E Q40183983-DC824DA6-61EF-4B39-95C0-65CE8B965E9A Q47130393-852A0470-147B-4C0A-918D-B644FB948196 Q47130878-FB47A569-BE5C-4B3D-AF0C-4B2FF021080B Q47393365-6391FA8A-34A0-4A48-8DF7-BC55B9B9027C Q47718879-5C6BC187-02FA-4CDB-8978-3EF6FEEF591F Q49821320-7350C9CC-9B9D-4C60-B954-895A64432575 Q50089384-0EC81805-CE03-40F0-9BF2-FA5B2993B193 Q54112267-EC8FFA8A-A68F-4B6F-891D-D291F20BA70C Q55321107-010105E6-CAC6-4836-AC66-791074B68784 Q58119177-40D4EC5D-D659-469D-85FC-3A4646F0B1CF Q58694216-B6D9E3A0-8B57-47E3-9F23-22EAD40FAE59

P2860

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.

http://www.wikidata.org/entity/Q38391922

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Safety and Efficacy of Nivolum ...... f a Randomized Clinical Trial.

@en

type

label

Safety and Efficacy of Nivolum ...... f a Randomized Clinical Trial.

@en

prefLabel

Safety and Efficacy of Nivolum ...... f a Randomized Clinical Trial.

@en

P1433

Q38391922-C99C136C-F623-4F82-8CB9-F369DFA76038

P1476

Q38391922-600D440C-44F3-48CC-A3DC-F8AD181FF46F

P2093

Q38391922-11E1656A-054D-4756-A8E5-D9FCCF91A26C

Q38391922-11FE5D31-3681-407F-B73E-12C63D15CEBA

Q38391922-32B7A0F6-2D0A-4825-9D5B-EA93AE92119C

Q38391922-588ECD93-6012-4F83-9FFB-C15C0E874DA8

Q38391922-71D26371-4BAA-412B-84A8-96A416FE7334

Q38391922-73246396-BF0C-446F-9F20-5168AEB7D253

Q38391922-959A4788-0101-4FB9-9156-9FA1F9FE0990

Q38391922-B682D957-899F-466E-9701-6574874BAD30

Q38391922-F5E1EC92-39C5-4D55-9420-DA16A3B9E3F4

Q38391922-FFB6702B-A68C-40F8-B534-3D43F80CFF7F

P2860

Q38391922-0113C1F9-E8BD-419D-BFF1-81809A7E3034

Q38391922-04CE98DB-4DBE-45B0-BA33-7FEAA96740FB

Q38391922-0E0BEC2B-A292-41A5-B554-2044A016FB88

Q38391922-107DA1D7-9CD8-4595-8EF3-668B4940D1C7

Q38391922-11D7F71D-AE2D-4EC5-AB1B-0F6D88A321BA

Q38391922-188B419E-769E-4E9B-961D-6FA477761A10

Q38391922-1FEEDCC8-BB9D-4724-8C2C-701277B6BB13

Q38391922-2D8E4CE8-526D-40BD-9A79-CEECC52C67A7

Q38391922-2ECD2BF6-3AAC-45F6-B35D-12DBF55250B3

Q38391922-32529BBA-2362-408F-B9C5-495E4F179910

P304

Q38391922-5DA0F534-9198-4E13-BAD1-2BDF4C87B561

P31

Q38391922-62BD86F0-3E91-4C2D-94BA-2E8356381126

P356

Q38391922-35D58CF5-5C07-4097-92A8-DB7D4BDE0A75

P433

Q38391922-45875FC2-DA6F-4279-AFCB-464335E4F9DA

P478

Q38391922-4F8A3BD6-7FAE-4A76-8866-B8B240B222D5

P577

Q38391922-9A7F0507-EAFA-46F0-B02C-3ABA0BB61E58

P698

Q38391922-0525A0DA-ADCE-49BB-90BC-78D96FC3C27E

P932

Q38391922-12B62C1A-BB46-4787-90B0-8355A0F4F4DB

P356

JAMAONCOL.2016.0775

P1433

P1476

Safety and Efficacy of Nivolum ...... f a Randomized Clinical Trial.

@en

P2093

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Bruce G Redman

http://www.w3.org/2001/XMLSchema#string

Elizabeth R Plimack

http://www.w3.org/2001/XMLSchema#string

Hans J Hammers

http://www.w3.org/2001/XMLSchema#string

Ian M Waxman

http://www.w3.org/2001/XMLSchema#string

Joel Jiang

http://www.w3.org/2001/XMLSchema#string

Robert J Motzer

http://www.w3.org/2001/XMLSchema#string

Saby George

http://www.w3.org/2001/XMLSchema#string

Scott S Tykodi

http://www.w3.org/2001/XMLSchema#string

Timothy M Kuzel

http://www.w3.org/2001/XMLSchema#string

P2860

Improved endpoints for cancer immunotherapy trials

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Nivolumab in previously untreated melanoma without BRAF mutation

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.

Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.

P304

1179-1186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAONCOL.2016.0775

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27243803

http://www.w3.org/2001/XMLSchema#string

P932

5568541

http://www.w3.org/2001/XMLSchema#string